Monday, 27 April 2009

Cardispan




Cardispan may be available in the countries listed below.


Ingredient matches for Cardispan



Levocarnitine

Levocarnitine is reported as an ingredient of Cardispan in the following countries:


  • Costa Rica

  • Guatemala

  • Honduras

  • Mexico

  • Nicaragua

  • Panama

International Drug Name Search

Sunday, 26 April 2009

Ranitidine-Glaxo Wellcome




Ranitidine-Glaxo Wellcome may be available in the countries listed below.


Ingredient matches for Ranitidine-Glaxo Wellcome



Ranitidine

Ranitidine is reported as an ingredient of Ranitidine-Glaxo Wellcome in the following countries:


  • Luxembourg

International Drug Name Search

Saturday, 25 April 2009

Dolophine


Dolophine is a brand name of methadone, approved by the FDA in the following formulation(s):


DOLOPHINE HYDROCHLORIDE (methadone hydrochloride - injectable; injection)



  • Manufacturer: MYLAN INSTITUTIONAL

    Approved Prior to Jan 1, 1982

    Strength(s): 10MG/ML [RLD]

DOLOPHINE HYDROCHLORIDE (methadone hydrochloride - tablet; oral)



  • Manufacturer: ROXANE

    Approved Prior to Jan 1, 1982

    Strength(s): 10MG [RLD][AA], 5MG [RLD][AA]

Has a generic version of Dolophine been approved?


Yes. The following products are equivalent to Dolophine:


methadone hydrochloride tablet; oral



  • Manufacturer: MALLINCKRODT

    Approval date: April 27, 2004

    Strength(s): 10MG [AA], 5MG [AA]


  • Manufacturer: SANDOZ

    Approval date: May 29, 1998

    Strength(s): 10MG [AA]


  • Manufacturer: THE PHARMANETWORK

    Approval date: November 25, 2009

    Strength(s): 10MG [AA]

METHADOSE (methadone hydrochloride tablet; oral)



  • Manufacturer: MALLINCKRODT

    Approval date: April 15, 1993

    Strength(s): 10MG [AA], 5MG [AA]

Note: No generic formulation of the following product is available.


  • methadone hydrochloride - injectable; injection

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Dolophine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Dolophine.

See also...

  • Dolophine Consumer Information (Wolters Kluwer)
  • Dolophine Solution Consumer Information (Wolters Kluwer)
  • Dolophine Consumer Information (Cerner Multum)
  • Methadone Consumer Information (Drugs.com)
  • Methadone Consumer Information (Wolters Kluwer)
  • Methadone Concentrate Consumer Information (Wolters Kluwer)
  • Methadone Dispersible Tablets Consumer Information (Wolters Kluwer)
  • Methadone Solution Consumer Information (Wolters Kluwer)
  • Diskets Consumer Information (Cerner Multum)
  • Methadone Consumer Information (Cerner Multum)
  • Methadone Hydrochloride AHFS DI Monographs (ASHP)

Emadine


Emadine is a brand name of emedastine ophthalmic, approved by the FDA in the following formulation(s):


EMADINE (emedastine difumarate - solution/drops; ophthalmic)



  • Manufacturer: ALCON

    Approval date: December 29, 1997

    Strength(s): 0.05% [RLD]

Has a generic version of Emadine been approved?


No. There is currently no therapeutically equivalent version of Emadine available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emadine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Ophthalmic compositions comprising emedastine and methods for their use
    Patent 5,441,958
    Issued: August 15, 1995
    Inventor(s): Yanni; John M. & Robertson; Stella M. & Okumura; Shigetoshi & Tanaka; Hitoshi & Saito; Tadayuki
    Assignee(s): Alcon Laboratories, Inc.
    Topical ophthalmic compositions comprising 1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)-benzimidazole and its ophthalmically acceptable acid addition salts have been found to be useful in treating allergic conjunctivitis and related ailments.
    Patent expiration dates:

    • December 8, 2013
      ✓ 
      Patent use: TREATMENT OF ALLERGIC CONJUNCTIVITIS



See also...

  • Emadine Drops Consumer Information (Wolters Kluwer)
  • Emadine Consumer Information (Cerner Multum)
  • Emadine Advanced Consumer Information (Micromedex)
  • Emadine AHFS DI Monographs (ASHP)
  • Emedastine Drops Consumer Information (Wolters Kluwer)
  • Emedastine ophthalmic Consumer Information (Cerner Multum)
  • Emedastine Ophthalmic Advanced Consumer Information (Micromedex)
  • Emedastine Difumarate AHFS DI Monographs (ASHP)

Friday, 24 April 2009

Penovet




Penovet may be available in the countries listed below.


In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Penovet



Benzylpenicillin

Benzylpenicillin procaine (a derivative of Benzylpenicillin) is reported as an ingredient of Penovet in the following countries:


  • Finland

  • Norway

  • Sweden

International Drug Name Search

Wednesday, 22 April 2009

Selenase




Selenase may be available in the countries listed below.


Ingredient matches for Selenase



Sodium Selenite

Sodium Selenite is reported as an ingredient of Selenase in the following countries:


  • Netherlands

  • Turkey

Sodium Selenite pentahydrate (a derivative of Sodium Selenite) is reported as an ingredient of Selenase in the following countries:


  • Austria

  • Germany

  • Switzerland

International Drug Name Search

Sunday, 19 April 2009

Eurax


Eurax is a brand name of crotamiton topical, approved by the FDA in the following formulation(s):


EURAX (crotamiton - cream; topical)



  • Manufacturer: RANBAXY

    Approved Prior to Jan 1, 1982

    Strength(s): 10% [RLD]

EURAX (crotamiton - lotion; topical)



  • Manufacturer: RANBAXY

    Approved Prior to Jan 1, 1982

    Strength(s): 10% [RLD][AT]

Has a generic version of Eurax been approved?


Yes. The following products are equivalent to Eurax:


CROTAN (crotamiton lotion; topical)



  • Manufacturer: SUMMERS

    Approved Prior to Jan 1, 1982

    Strength(s): 10% [AT]

Note: No generic formulation of the following product is available.


  • crotamiton - cream; topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eurax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Eurax.

See also...

  • Eurax Consumer Information (Drugs.com)
  • Eurax Cream Consumer Information (Wolters Kluwer)
  • Eurax Lotion Consumer Information (Wolters Kluwer)
  • Eurax Consumer Information (Cerner Multum)
  • Eurax Topical Advanced Consumer Information (Micromedex)
  • Eurax AHFS DI Monographs (ASHP)
  • Crotamiton Cream Consumer Information (Wolters Kluwer)
  • Crotamiton Lotion Consumer Information (Wolters Kluwer)
  • Crotamiton topical Consumer Information (Cerner Multum)
  • Crotamiton Topical Advanced Consumer Information (Micromedex)
  • Crotamiton AHFS DI Monographs (ASHP)

Friday, 17 April 2009

Wellbutrin XL


See also: Generic Wellbutrin, Generic Wellbutrin SR


Wellbutrin XL is a brand name of bupropion, approved by the FDA in the following formulation(s):


WELLBUTRIN XL (bupropion hydrochloride - tablet, extended release; oral)



  • Manufacturer: VALEANT INTL

    Approval date: August 28, 2003

    Strength(s): 150MG [RLD][AB3], 300MG [AB3]

Has a generic version of Wellbutrin XL been approved?


A generic version of Wellbutrin XL has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Wellbutrin XL and have been approved by the FDA:


bupropion hydrochloride tablet, extended release; oral



  • Manufacturer: ACTAVIS

    Approval date: August 15, 2008

    Strength(s): 300MG [AB3]


  • Manufacturer: ACTAVIS

    Approval date: November 26, 2008

    Strength(s): 150MG [AB3]


  • Manufacturer: ANCHEN PHARMS

    Approval date: December 14, 2006

    Strength(s): 150MG [AB3], 300MG [AB3]


  • Manufacturer: IMPAX LABS

    Approval date: December 15, 2006

    Strength(s): 300MG [AB3]


  • Manufacturer: IMPAX LABS

    Approval date: November 26, 2008

    Strength(s): 150MG [AB3]


  • Manufacturer: MYLAN

    Approval date: July 14, 2010

    Strength(s): 150MG [AB3], 300MG [AB3]


  • Manufacturer: WATSON LABS

    Approval date: June 13, 2007

    Strength(s): 300MG [AB3]


  • Manufacturer: WATSON LABS

    Approval date: November 26, 2008

    Strength(s): 150MG [AB3]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Wellbutrin XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents


Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.




  • Delayed release tablet of bupropion hydrochloride
    Patent 6,096,341
    Issued: August 1, 2000
    Inventor(s): Seth; Pawan
    Assignee(s): Pharma Pass LLC
    The invention provides a controlled release tablet, free of stabilizer and free of pore-forming agent comprising: (i) a core consisting essentially of bupropion hydrochloride, a binder and a lubricant; and (ii) a coating consisting essentially of a water-insoluble, water-permeable film-forming polymer, a plasticizer and a water-soluble polymer.
    Patent expiration dates:

    • October 30, 2018



See also...

  • Wellbutrin XL Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Wellbutrin XL Consumer Information (Cerner Multum)
  • Wellbutrin XL Advanced Consumer Information (Micromedex)
  • Bupropion Consumer Information (Drugs.com)
  • Bupropion Consumer Information (Wolters Kluwer)
  • Bupropion Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Hydrobromide Extended-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Sustained-Release Tablets Consumer Information (Wolters Kluwer)
  • Bupropion Consumer Information (Cerner Multum)
  • Bupropion Advanced Consumer Information (Micromedex)
  • Bupropion Hydrochloride AHFS DI Monographs (ASHP)

Wednesday, 15 April 2009

Balancid Novum




Balancid Novum may be available in the countries listed below.


Ingredient matches for Balancid Novum



Calcium Carbonate

Calcium Carbonate is reported as an ingredient of Balancid Novum in the following countries:


  • Denmark

  • Finland

Magnesium Hydroxide

Magnesium Hydroxide is reported as an ingredient of Balancid Novum in the following countries:


  • Denmark

  • Finland

International Drug Name Search

Sunday, 12 April 2009

Doctadryle




Doctadryle may be available in the countries listed below.


Ingredient matches for Doctadryle



Calcitonin

Calcitonin is reported as an ingredient of Doctadryle in the following countries:


  • Greece

International Drug Name Search

Saturday, 11 April 2009

dexbrompheniramine, hydrocodone, and phenylephrine


Generic Name: dexbrompheniramine, hydrocodone, and phenylephrine (DEX brom fen IR a meen, HYE dro KOE done, FEN il EFF rin)

Brand Names: Cytuss-HC NR, H-C Tussive-NR, Histussin HC


What is dexbrompheniramine, hydrocodone, and phenylephrine?

Brompheniramine is an antihistamine that reduces the natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.


Hydrocodone is a narcotic cough suppressant.


Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of dexbrompheniramine, hydrocodone, and phenylephrine is used to treat nasal congestion, sneezing, runny nose, itchy or water eyes, and cough caused by allergies or the common cold.


Dexbrompheniramine, hydrocodone, and phenylephrine may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about dexbrompheniramine, hydrocodone, and phenylephrine?


Do not use this medication if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take a cough and cold medicine before the MAO inhibitor has cleared from your body.

You should not use dexbrompheniramine, hydrocodone, and phenylephrine if you are allergic to it, or if you have severe or uncontrolled high blood pressure, coronary artery disease, ischemic heart disease (reduced circulation of blood to the heart), narrow-angle glaucoma, peptic ulcer, if you are unable to urinate, or if you are pregnant or breast-feeding.


Hydrocodone may be habit-forming and should be used only by the person it was prescribed for. This medication should never be shared with another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it. Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children. Dexbrompheniramine, hydrocodone, and phenylephrine should not be given to a child younger than 6 years old.

What should I discuss with my healthcare provider before taking dexbrompheniramine, hydrocodone, and phenylephrine?


Do not use this medication if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take a cough and cold medicine before the MAO inhibitor has cleared from your body. You should not use dexbrompheniramine, hydrocodone, or phenylephrine, if you have ever had an allergic reaction to it, or if you have:

  • severe or uncontrolled high blood pressure;




  • coronary artery disease;




  • an enlarged prostate;




  • narrow-angle glaucoma;




  • peptic ulcer;




  • asthma;




  • pheochromocytoma;




  • if you are breast-feeding a baby; or




  • if you are having an asthma attack.



If you have certain conditions, you may need a dose adjustment or special tests to safely take dexbrompheniramine, hydrocodone, and phenylephrine. Before taking this medication, tell your doctor if you have:



  • heart disease or high blood pressure;




  • asthma, COPD, or other breathing disorder;




  • diabetes;




  • glaucoma;




  • thyroid disorder;




  • a history of head injury or brain tumor;




  • enlarged prostate, urination problems.




FDA pregnancy category C. This medication may be harmful to an unborn baby. Hydrocodone can cause breathing problems or addiction/withdrawal symptoms in a newborn. Do not take this medication while you are pregnant. This medication can pass into breast milk and may harm a nursing baby. Do not take this medication if you are breast-feeding a baby. Hydrocodone may be habit-forming and should be used only by the person it was prescribed for. This medication should never be shared with another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it. Older adults may be more likely to have side effects from this medication.

How should I take dexbrompheniramine, hydrocodone, and phenylephrine?


Take this medication exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label. Cold medicine is usually taken for only a short time until your symptoms clear up.


Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children. Dexbrompheniramine, hydrocodone, and phenylephrine should not be given to a child younger than 6 years old. Take the medicine with a full glass of water.

Measure liquid medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache or skin rash. Store dexbrompheniramine, hydrocodone, and phenylephrine at room temperature away from moisture and heat.

Keep track of how much of this medicine has been used from the bottle. Hydrocodone is a drug of abuse and you should be aware if any person in the household is using this medicine improperly or without a prescription.


What happens if I miss a dose?


Since cough and cold medicine is usually taken only as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention if you think you have used too much of this medicine. An overdose of hydrocodone can be fatal.

Overdose symptoms may include feeling restless or hyperactive, agitation, dizziness, confusion, hallucinations, fast or uneven heart rate, tremor, hallucinations, extreme drowsiness, loss of coordination, warmth or redness in your face, fever, cold or clammy skin, dilated pupils, pinpoint pupils, slow heart rate, blue-colored lips or fingernails, seizure (convulsions), weak or shallow breathing, or breathing that stops.


What should I avoid while taking dexbrompheniramine, hydrocodone, and phenylephrine?


This medication can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert. Avoid drinking alcohol while you are taking this medication.

Tell your doctor if you regularly use other medicines that make you sleepy (such as pain medication, sleeping pills, muscle relaxers, and medicine for seizures, depression or anxiety). They can add to sleepiness caused by dexbrompheniramine, hydrocodone, and phenylephrine.


Do not use any other over-the-counter cold, allergy, or pain medication without first asking your doctor or pharmacist. Brompheniramine or phenylephrine are contained in many medicines available over the counter. If you take certain products together you may accidentally take too much of a certain drug. Read the label of any other medicine you are using to see if it contains brompheniramine or phenylephrine.

Dexbrompheniramine, hydrocodone, and phenylephrine side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • shallow breathing, slow heartbeat;




  • fast or pounding heartbeat;




  • slow heart rate, weak pulse, fainting, slow breathing (breathing may stop);




  • confusion, hallucinations, unusual thoughts or behavior;




  • seizure (convulsions);




  • painful or difficult urination;




  • urinating less than usual or not at all; or




  • severe dizziness, anxiety, fear, or tremors.



Less serious side effects may include:



  • dizziness, drowsiness, headache;




  • feeling restless or nervous;




  • sleep problems (insomnia);




  • nausea, vomiting, heartburn, loss of appetite;




  • dry mouth;




  • increased urination; or




  • blurred vision.



This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect dexbrompheniramine, hydrocodone, and phenylephrine?


Before taking this medication, tell your doctor if you regularly use other medicines that make you sleepy (such as narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, anxiety, or mental illness). They can add to sleepiness caused by dexbrompheniramine or hydrocodone.

Also tell your doctor about all other medicines you use, especially:



  • medicines to treat high blood pressure;




  • indomethacin (Indocin);




  • mecamylamine (Inversine);




  • methyldopa (Aldomet);




  • reserpine;




  • a beta-blocker such as atenolol (Tenormin), carteolol (Cartrol), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), timolol (Blocadren), and others; or




  • an antidepressant such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.



This list is not complete and there may be other drugs that can interact with dexbrompheniramine, hydrocodone, and phenylephrine. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More dexbrompheniramine, hydrocodone, and phenylephrine resources


  • Dexbrompheniramine, hydrocodone, and phenylephrine Side Effects (in more detail)
  • Dexbrompheniramine, hydrocodone, and phenylephrine Use in Pregnancy & Breastfeeding
  • Dexbrompheniramine, hydrocodone, and phenylephrine Drug Interactions
  • Dexbrompheniramine, hydrocodone, and phenylephrine Support Group
  • 0 Reviews for Dexbrompheniramine, hydrocodone, and phenylephrine - Add your own review/rating


Compare dexbrompheniramine, hydrocodone, and phenylephrine with other medications


  • Cough
  • Cough and Nasal Congestion
  • Hay Fever
  • Nasal Congestion


Where can I get more information?


  • Your pharmacist can provide more information about dexbrompheniramine, hydrocodone, and phenylephrine.

See also: dexbrompheniramine, hydrocodone, and phenylephrine side effects (in more detail)


Tuesday, 7 April 2009

Melus-Medichrom




Melus-Medichrom may be available in the countries listed below.


Ingredient matches for Melus-Medichrom



Meloxicam

Meloxicam is reported as an ingredient of Melus-Medichrom in the following countries:


  • Greece

International Drug Name Search

Friday, 3 April 2009

Septra DS


See also: Generic Septra


Septra DS is a brand name of sulfamethoxazole/trimethoprim, approved by the FDA in the following formulation(s):


SEPTRA DS (sulfamethoxazole; trimethoprim - tablet; oral)



  • Manufacturer: MONARCH PHARMS

    Approved Prior to Jan 1, 1982

    Strength(s): 800MG;160MG [AB]

Has a generic version of Septra DS been approved?


Yes. The following products are equivalent to Septra DS:


SULFAMETHOPRIM-DS (sulfamethoxazole; trimethoprim tablet; oral)



  • Manufacturer: NOVEL LABS INC

    Approval date: February 15, 1985

    Strength(s): 800MG;160MG [AB]

SULFAMETHOXAZOLE AND TRIMETHOPRIM (sulfamethoxazole; trimethoprim tablet; oral)



  • Manufacturer: AMNEAL PHARMS NY

    Approval date: January 27, 2005

    Strength(s): 800MG;160MG [AB]


  • Manufacturer: AUROBINDO PHARMA

    Approval date: February 16, 2010

    Strength(s): 800MG;160MG [AB]


  • Manufacturer: GLENMARK GENERICS

    Approval date: December 22, 2010

    Strength(s): 800MG;160MG [AB]


  • Manufacturer: MUTUAL PHARM

    Approval date: August 25, 1986

    Strength(s): 800MG;160MG [AB]


  • Manufacturer: VINTAGE

    Approval date: January 25, 2007

    Strength(s): 800MG;160MG [AB]


  • Manufacturer: VISTA PHARMS

    Approval date: October 7, 2005

    Strength(s): 800MG;160MG [AB]

SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH (sulfamethoxazole; trimethoprim tablet; oral)



  • Manufacturer: SANDOZ

    Approval date: May 19, 1982

    Strength(s): 800MG;160MG [AB]


  • Manufacturer: TEVA

    Approval date: June 2, 1987

    Strength(s): 800MG;160MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Septra DS. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Septra DS.

See also...

  • Septra DS Consumer Information (Cerner Multum)
  • Septra DS Advanced Consumer Information (Micromedex)
  • Sulfamethoxazole/Trimethoprim Consumer Information (Wolters Kluwer)
  • Sulfamethoxazole/Trimethoprim Suspension Consumer Information (Wolters Kluwer)
  • Sulfamethoxazole/Trimethoprim Tablets Consumer Information (Wolters Kluwer)
  • Sulfamethoxazole and trimethoprim Consumer Information (Cerner Multum)
  • Apo-Sulfatrim Advanced Consumer Information (Micromedex)
  • Novo-Trimel Advanced Consumer Information (Micromedex)
  • Nu-Cotrimox Advanced Consumer Information (Micromedex)
  • Septa Pediatric Advanced Consumer Information (Micromedex)
  • Sulfamethoxazole/trimethoprim Advanced Consumer Information (Micromedex)
  • Sulfamethoxazole/trimethoprim Intravenous Advanced Consumer Information (Micromedex)
  • Trimethoprim and sulfamethoxazole Advanced Consumer Information (Micromedex)
  • Trimethoprim and sulfamethoxazole Intravenous Advanced Consumer Information (Micromedex)